Inactivation of TLR9 by a suppressive oligodeoxynucleotides can ameliorate the clinical signs of EAN

Immunological Investigations

Volumn 41, Issue 2, 2012, Pages 171-182

  Wang, Yu Zhong ^a   Liang, Qiu Hua ^b   Ramkalawan, Hhoonisha ^a   Zhang, Wei ^a   Zhou, Wen Bin ^a   Xiao, Bo ^a   Tian, Fa Fa ^a   Yang, Huan ^a   Li, Jing ^a   Zhang, Yong ^c   Xu, Ning An ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cytokine; Experimental autoimmune neuritis; Innate immunity; Oligodeoxynucleotides; TLR9

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; GAMMA INTERFERON; MYELIN BASIC PROTEIN; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE NEURITIS; HISTOPATHOLOGY; IMMUNIZATION; LYMPH NODE CELL; MALE; NEURITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; FREUND'S ADJUVANT; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNIZATION; MALE; MYELIN P2 PROTEIN; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED LEW; TOLL-LIKE RECEPTOR 9;

EID: 83655165127     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.604864     Document Type: Article

References (20)

1. Abreu, M. T., Thomas, L. S., Arnold, E. T., Lukasek, K., Michelsen, K. S., Arditi, M. (2003). TLR signaling at the intestinal epithelial interface. J. Endotoxin Res. 9: 322-330.
2. Deng, Y. N., Zhou, W. B. (2007). Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis. Neuroimmunomodulation 14:337-343.
3. Gold, R., Archelos, J. J., Hartung, H. P. (1999). Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol. 9:343-360. (Pubitemid 29157720)
4. Gursel, I., Gursel, M., Yamada, H., Ishii, K. J., Takeshita, F., Klinman, D. M. (2003). Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 171:1393-1400. (Pubitemid 36900072)
5. Hahn, A. F. (1996). Experimental allergic neuritis (EAN) as a model for the immunemediated demyelinating neuropathies. Revue Neurologique 152:328-332. (Pubitemid 26228343)
6. Ichikawa, H. T., Williams, L. P., Segal, B. M. (2002). Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169:2781-2787. (Pubitemid 34921028)
7. Krieg, A. M. (2000). Immune effects and mechanisms of action of CpG motifs. Vaccine 19:618-622.
8. Krieg, A. M., Wu, T., Weeratna, R., Efler, S. M., Love-Homan, L., Yang, L., Yi, A. K., Short, D., Davis, H. L. (1998). Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA 95:12631-12636. (Pubitemid 28483816)
9. Lee, K. S., Scanga, C. A., Bachelder, E. M., Chen, Q., Snapper, C. M. (2007). TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell. Immunol. 245:103-110. (Pubitemid 46921170)
10. Marta, M., Andersson, A., Isaksson, M., Kampe, O., Lobell, A. (2008). Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Euro. J. Immunol. 38:565-575.
11. Matsumoto, Y., Kim, G., Tanuma, N. (2000). Characterization of T cell receptor associated with the development of P2 peptide-induced autoimmune neuritis. J. Neuroimmunol. 102:67-72.
12. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., Janeway, C.A., Jr. (1998). MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2:253-258. (Pubitemid 128373651)
13. Patel, B. A., Gomis, S., Dar, A., Willson, P. J., Babiuk, L. A., Potter, A., Mutwiri, G., Tikoo, S. K. (2008). Oligodeoxynucleotides containing CpG motifs (CpG-ODN) predominantly induce Th1-type immune response in neonatal chicks. Devel. Compar. Immunol. 32:1041-1049.
14. Ropper, A. H. (1992). The Guillain-Barre syndrome. N. Engl. J. Med. 326:1130-1136.
15. Sun, J., Walsh, M., Villarino, A. V., Cervi, L., Hunter, C. A., Choi, Y., Pearce, E. J. (2005). TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development. J. Immunol. 174:742-751. (Pubitemid 40094268)
16. Takeda, K., Kaisho, T., Akira, S. (2003). Toll-like receptors. Ann. Rev. Immunol. 21: 335-376. (Pubitemid 37174535)
17. Viglianti, G. A., Lau, C. M., Hanley, T. M., Miko, B. A., Shlomchik, M. J., Marshak-Rothstein, A. (2003). Activation of autoreactive B cells by CpG dsDNA. Immunity 19:837-847. (Pubitemid 37542304)
18. Wolf, N. A., Amouzegar, T. K., Swanborg, R. H. (2007). Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 185:115-122. (Pubitemid 46497453)
19. Zarember, K. A., Godowski, P. J. (2002). Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168:554-561. (Pubitemid 34049553)
20. Zeuner, R. A., Ishii, K. J., Lizak, M. J., Gursel, I., Yamada, H., Klinman, D. M., Verthelyi, D. (2002). Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheumat. 46:2219-2224.